Infinity Pharmaceuticals Inc. (INFI) Announces Closing of Secondary Offering of Common Stock and Exercise of Over-Allotment Option
4/16/2013 11:05:23 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the closing of an underwritten public offering of its common stock, at a price of $40.00 per share, by existing shareholders Beacon Company and Rosebay Medical Company L.P., including shares that were transferred to Beacon and Rosebay by Purdue Pharma L.P., an associated company of Beacon and Rosebay. The total number of shares of common stock sold was 11,416,565, composed of 10,000,000 shares of common stock initially sold and an additional 1,416,565 shares of common stock sold pursuant to the exercise of the underwriters’ over-allotment option. 5,708,282 shares of common stock were sold by Beacon and 5,708,283 shares of common stock were sold by Rosebay. Immediately following the closing, Beacon, Rosebay and Purdue will not hold any shares of Infinity. Infinity did not sell any shares or receive any proceeds from the offering, and the total number of shares of its outstanding common stock has not changed as a result of the offering.
comments powered by